Zydus Lifesciences acquires UK-based LiqMeds

Ahmedabad: Zydus Lifesciences Limited, through its wholly-owned subsidiary, Zydus Pharmaceuticals UK Limited, officially declared the purchase of the LiqMeds Group of companies headquartered in the United Kingdom. This group possesses expertise and specialization in the development, production, and global distribution of oral liquid products, currently marketed through partnerships. One of the group's subsidiaries, LM Manufacturing Limited (LMML), operates an oral liquids manufacturing facility in Weedon, Northampton, UK, supplying products to both the US and UK markets.

Zydus will provide an initial payment of GBP 68 million, with additional annual earn-outs until 2026 contingent upon the achievement of predefined milestones related to the acquisition of the LiqMeds Group of companies. The transaction is expected to enhance Zydus' earnings per share (EPS) starting from the first year following the acquisition.

Speaking on the development, Dr Sharvil Patel, Managing Director of Zydus Lifesciences Limited, said, “We believe that liquid orals is a large, growing market and serves unmet needs with significant new market expansion opportunities. In line with our patient-centric approach, we believe that oral liquid formulations would help geriatric and paediatric patients, bringing in greater ease of convenience and therapy compliance.”